Key Highlights
- Third quarter Revenue was USD 759.3 million against a USD 740.07 million estimate and USD 496.7 million a year earlier.
- EPS was USD 0.03 against an estimate of negative USD 0.01, and GAAP diluted EPS was USD 0.01.
- Net income was USD 6.4 million against a net loss of USD 24.4 million; adjusted EBITDA was USD 16.1 million.
- Updated 2026 revenue guidance is USD 2.97 billion to USD 3.00 billion, against USD 2.92 billion to USD 3.00 billion.
Clover Health Investments, Corp. (NASDAQ:CLOV) opened the reporting window with a Leadership change: on November 2 its board named the interim chief financial officer to the role permanently, effective November 4, and appointed its controller as chief accounting officer. The announcement came alongside third quarter results that included revenue of USD 759.3 million and updated 2026 guidance across every metric.
How the Appointments Fit the Quarter
The finance team that carries the permanent titles reported a third quarter with 158,907 Medicare Advantage members, against 109,226 a year earlier, and average membership of 158,383 against 108,231. The chief financial officer referred to a first full year of GAAP Net Income profitability for 2026 and to its largest member cohorts maturing. Chief executive Andrew Toy tied the results to Clover Assistant and to a flagship PPO that holds about 98% of members and received a 5 Star rating for Payment Year 2028.
The company also said its 2027 annual enrollment period is tracking well, with significant growth tied to product positioning in core markets.
Results Around the Appointments
Total revenues were USD 759.3 million, up 52.9%, against an estimate of USD 740.07 million. EPS was USD 0.03 against an estimate of negative USD 0.01; GAAP diluted EPS in the statements was USD 0.01 against negative USD 0.05. Net income was USD 6.4 million against a net loss of USD 24.4 million.
Premiums earned were USD 748.8 million, and the insurance BER was 91.1% against 93.5%. Consolidated Gross Profit was USD 129.8 million against USD 73.2 million, and adjusted EBITDA was USD 16.1 million against USD 2.1 million. For the nine months, net income was USD 61.8 million against a net loss of USD 36.2 million.
Cash, Financing and Updated Guidance
Total cash, cash equivalents and investments were USD 512.6 million, against USD 395.9 million a year earlier. Cash and cash equivalents on the Balance Sheet were USD 268.1 million at September 30, against USD 78.3 million at year end. Operating Cash Flow for nine months was USD 203.5 million against USD 1.2 million.
Current 2026 guidance, with the previous range in parentheses, is total revenues of USD 2.97 billion to USD 3.00 billion (USD 2.92 billion to USD 3.00 billion), GAAP net income of USD 25 million to USD 35 million (USD 20 million to USD 35 million), and consolidated gross profit of USD 540 million to USD 555 million (USD 525 million to USD 555 million). Adjusted EBITDA is guided at USD 75 million to USD 85 million (USD 70 million to USD 85 million), and average Medicare Advantage membership at 157,000 to 158,000 (156,000 to 158,000).
Guidance Versus Reported Results
Nine-month total revenues of USD 2.252 billion sit alongside full-year guidance of USD 2.97 billion to USD 3.00 billion, and nine-month adjusted EBITDA of USD 97.2 million sits alongside guidance of USD 75 million to USD 85 million. Nine-month GAAP net income of USD 61.8 million compares with guidance of USD 25 million to USD 35 million.
Management named a few dated items: the leadership appointments effective November 4 and the 2027 enrollment period. It also said it believes Operating Leverage and Star ratings performance support Earnings expansion in 2027.






Please wait processing your request...